Higher dose of Wegovy provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Higher dose of Wegovy provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

• Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo¹
• Safety and tolerability of the higher dose of Wegovy (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg)¹
• The STEP UP data add to the existing evidence base on the value of Wegovy in delivering significant weight loss and health gains for people living with obesity
  
  

Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.¹

“The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide’s established safety profile. This may offer another option to people who do not attain their weight goals,” said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. “We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.”

STEP UP co-primary endpoints at 72 weeks^*1:
                                              semaglutide 7.2 mg         semaglutide 2.4 mg         Placebo
Weight loss                             20.7%                                17.5%                                      2.4%